180 related articles for article (PubMed ID: 22153914)
1. Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients.
Ponti G; Pollio A; Cesinaro AM; Pellacani G; Magnoni C; Seidenari S
Cancer Epidemiol; 2012 Jun; 36(3):303-5. PubMed ID: 22153914
[TBL] [Abstract][Full Text] [Related]
2. Impact of mitotic activity on the pathological substaging of pT1 cutaneous melanoma.
de Waal AC; van Harten-Gerritsen AS; Aben KK; Kiemeney LA; van Rossum MM; Blokx WA
Br J Dermatol; 2014 Apr; 170(4):874-7. PubMed ID: 24593233
[TBL] [Abstract][Full Text] [Related]
3. Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma.
Casper DJ; Ross KI; Messina JL; Sondak VK; Bodden CN; McCardle TW; Glass LF
Am J Dermatopathol; 2010 Oct; 32(7):650-4. PubMed ID: 20559123
[TBL] [Abstract][Full Text] [Related]
4. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas.
Gimotty PA; Elder DE; Fraker DL; Botbyl J; Sellers K; Elenitsas R; Ming ME; Schuchter L; Spitz FR; Czerniecki BJ; Guerry D
J Clin Oncol; 2007 Mar; 25(9):1129-34. PubMed ID: 17369575
[TBL] [Abstract][Full Text] [Related]
5. How staging of thin melanoma is changed after the introduction of TNM 7th edition: a population-based analysis.
Caldarella A; Fancelli L; Manneschi G; Chiarugi A; Nardini P; Crocetti E
J Cancer Res Clin Oncol; 2016 Jan; 142(1):73-6. PubMed ID: 26113451
[TBL] [Abstract][Full Text] [Related]
6. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis.
Donizy P; Kaczorowski M; Leskiewicz M; Zietek M; Pieniazek M; Kozyra C; Halon A; Matkowski R
Oncol Rep; 2014 Dec; 32(6):2735-43. PubMed ID: 25310673
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of tumor mitotic rate and other clinicopathologic factors in patients with locoregional recurrences of melanoma.
Murali R; Moncrieff MD; Hong J; Cooper CL; Shingde MV; Samuel DG; Thompson JF; Scolyer RA
Ann Surg Oncol; 2010 Nov; 17(11):2992-9. PubMed ID: 20425144
[TBL] [Abstract][Full Text] [Related]
8. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.
Francken AB; Shaw HM; Thompson JF; Soong SJ; Accortt NA; Azzola MF; Scolyer RA; Milton GW; McCarthy WH; Colman MH; McGovern VJ
Ann Surg Oncol; 2004 Apr; 11(4):426-33. PubMed ID: 15070604
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
10. Pathologic and clinical features influencing outcome of thin cutaneous melanoma: correlation with newly proposed staging system.
Finley JW; Gibbs JF; Rodriguez LM; Letourneau R; Driscoll D; Kraybill W
Am Surg; 2000 Jun; 66(6):527-31; discussion 531-2. PubMed ID: 10888127
[TBL] [Abstract][Full Text] [Related]
11. Sentinel node biopsy should be offered in thin melanoma with mitotic rate greater than one.
Sekula-Gibbs SA; Shearer MA
Dermatol Surg; 2011 Aug; 37(8):1080-8. PubMed ID: 21635622
[TBL] [Abstract][Full Text] [Related]
12. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging.
Gimotty PA; Guerry D; Ming ME; Elenitsas R; Xu X; Czerniecki B; Spitz F; Schuchter L; Elder D
J Clin Oncol; 2004 Sep; 22(18):3668-76. PubMed ID: 15302909
[TBL] [Abstract][Full Text] [Related]
13. Implementation of the 7th edition AJCC staging system: Effects on staging and survival for pT1 melanoma. A Dutch population based study.
Oude Ophuis CM; Louwman MW; Grünhagen DJ; Verhoef K; van Akkooi AC
Int J Cancer; 2017 Apr; 140(8):1802-1808. PubMed ID: 28109000
[TBL] [Abstract][Full Text] [Related]
14. Mitotic rate in cutaneous melanomas ≤1 mm in thickness: a prospective study.
Litzner BR; Etufugh CN; Stepenaskie S; Hynan LS; Cockerell CJ
Am J Dermatopathol; 2012 Dec; 34(8):827-32. PubMed ID: 22878366
[TBL] [Abstract][Full Text] [Related]
15. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
[TBL] [Abstract][Full Text] [Related]
16. Clinical, histological and quantitative prognostic factors in cutaneous malignant melanoma.
Karjalainen J; Eskelinen M; Kosma VM; Lipponen P; Tuominen L; Alhava E
Anticancer Res; 1992; 12(5):1507-11. PubMed ID: 1444213
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous melanomas that defy conventional prognostic indicators.
McCarthy WH; Shaw HM; McCarthy SW; Rivers JK; Thompson JF
Semin Oncol; 1996 Dec; 23(6):709-13. PubMed ID: 8970591
[TBL] [Abstract][Full Text] [Related]
18. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.
Vaquerano J; Kraybill WG; Driscoll DL; Cheney R; Kane JM
Ann Surg Oncol; 2006 Feb; 13(2):198-204. PubMed ID: 16418885
[TBL] [Abstract][Full Text] [Related]
19. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma.
Barnhill RL; Katzen J; Spatz A; Fine J; Berwick M
J Cutan Pathol; 2005 Apr; 32(4):268-73. PubMed ID: 15769275
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society.
Leiter U; Buettner PG; Eigentler TK; Garbe C
J Clin Oncol; 2004 Sep; 22(18):3660-7. PubMed ID: 15302905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
